Comparing Zealand Pharma A/S (OTCMKTS:ZLDPF) and Siemens Gamesa Renewable Energy (OTCMKTS:GCTAY)

Siemens Gamesa Renewable Energy (OTCMKTS:GCTAY) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both energy companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Profitability

This table compares Siemens Gamesa Renewable Energy and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Siemens Gamesa Renewable Energy	N/A	N/A	N/A
Zealand Pharma A/S	-1,725.03%	-15.24%	-13.77%

Analyst Recommendations

This is a breakdown of current recommendations for Siemens Gamesa Renewable Energy and Zealand Pharma A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siemens Gamesa Renewable Energy	0	0	0	0	0.00
Zealand Pharma A/S	0	0	1	2	3.67

Valuation and Earnings

This table compares Siemens Gamesa Renewable Energy and Zealand Pharma A/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siemens Gamesa Renewable Energy	$12.19 billion	1.05	-$749.21 million	N/A	N/A
Zealand Pharma A/S	$9.09 million	509.12	-$102.18 million	($2.36)	-27.61

Zealand Pharma A/S has lower revenue, but higher earnings than Siemens Gamesa Renewable Energy.

Volatility & Risk

Siemens Gamesa Renewable Energy has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

About Siemens Gamesa Renewable Energy

Siemens Gamesa supplies wind turbines and power solutions to customers. The company is a global leader in the renewable energy industry specifically in the development, installation, maintenance, and manufacturing of wind turbines. Siemens Gamesa’s vision is to be the global leader in the renewable energy industry driving the transition towards a sustainable world. Siemens Gamesa was founded in 1976 and is based in Zamudio, Spain.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.